Holen Sie sich die Stockscreener-App
9.025
3.09%
0.285
Schlusskurs vom Vortag:
$8.74
Offen:
$8.86
24-Stunden-Volumen:
284.16K
Relative Volume:
0.64
Marktkapitalisierung:
$533.25M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-153.16M
KGV:
-2.4458
EPS:
-3.69
Netto-Cashflow:
$-134.48M
1W Leistung:
+4.22%
1M Leistung:
+14.78%
6M Leistung:
-31.01%
1J Leistung:
-60.03%
1-Tages-Spanne:
$8.57
$9.10
1-Wochen-Bereich:
$8.46
$9.36
52-Wochen-Spanne:
$6.85
$24.76
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Firmenname
Cullinan Therapeutics Inc
Sektor
Branche
Telefon
617-410-4650
Adresse
ONE MAIN STREET, CAMBRIDGE
Vergleichen Sie CGEM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
9.035 | 512.25M | 0 | -153.16M | -134.48M | -3.69 |
|
ONC
Beone Medicines Ltd Adr
|
256.05 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.232 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.08 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.70 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-05-01 | Eingeleitet | Stifel | Buy |
| 2024-04-15 | Eingeleitet | William Blair | Outperform |
| 2024-02-15 | Eingeleitet | Wedbush | Outperform |
| 2023-06-15 | Eingeleitet | TD Cowen | Outperform |
| 2022-11-21 | Eingeleitet | BTIG Research | Buy |
| 2021-04-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | Eingeleitet | Evercore ISI | Outperform |
| 2021-02-02 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-02-02 | Eingeleitet | SVB Leerink | Outperform |
| 2021-02-01 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cullinan Therapeutics Inc Aktie (CGEM) Neueste Nachrichten
Cullinan Therapeutics Licenses Rights to Velinotamig from Genrix Bio - Contract Pharma
Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix - MENAFN.com
Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix By Stocktwits - Investing.com India
Transcript : Cullinan Therapeutics, Inc.Special Call - marketscreener.com
Cullinan expands autoimmune focus with new T cell engager license By Investing.com - Investing.com South Africa
Cullinan (CGEM) Secures Global Rights for Velinotamig from Genri - GuruFocus
Cullinan Therapeutics (CGEM) Secures Exclusive License for Velin - GuruFocus
Cullinan Management Enters Global License Agreement with Genrix - TipRanks
Cullinan Therapeutics in pact with Genrix Bio for velinotamig (CGEM:NASDAQ) - Seeking Alpha
Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases | CGEM Stock News - GuruFocus
Cullinan Therapeutics Licenses Rights to Velinotamig - marketscreener.com
Cullinan Therapeutics Licenses Rights to Velinotamig, a - GlobeNewswire
Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific ... - Eagle-Tribune
Bank of America Corp DE Cuts Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Sold by Nuveen Asset Management LLC - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Sees Significant Decline in Short Interest - Defense World
Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILI - GuruFocus
Cullinan Therapeutics IncTaiho Oncology And Cullinan Therapeutics Publish Positive Rezilient1 Trial Results - marketscreener.com
Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology - PR Newswire
ProShare Advisors LLC Acquires 4,124 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics to Host Analyst and Investor Event at - GlobeNewswire
Cullinan Therapeutics to Host Analyst and Investor Event at 2025 - GuruFocus
Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference | CGEM Stock News - GuruFocus
Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference - The Globe and Mail
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Sold by D. E. Shaw & Co. Inc. - Defense World
Ameriprise Financial Inc. Raises Stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics (CGEM) Reveals Promising Phase 2b Results - GuruFocus
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology - GuruFocus
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology Announce Positive Results from REZILIENT1 Trial of Zipalertinib in Advanced Lung Cancer Patients - Nasdaq
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025 - GlobeNewswire
Northern Trust Corp Raises Stock Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
115,000 Shares in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Acquired by BNP Paribas Financial Markets - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stake Boosted by Price T Rowe Associates Inc. MD - Defense World
Cullinan Therapeutics (CGEM) Projected to Announce Quarterly Earnings on Wednesday - Defense World
Cullinan Therapeutics (CGEM): UBS Lowers Price Target but Mainta - GuruFocus
Cullinan Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Cullinan Therapeutics (NASDAQ:CGEM) Price Target Lowered to $24.00 at UBS Group - Defense World
UBS Adjusts Price Target on Cullinan Therapeutics to $24 From $30, Maintains Buy Rating - marketscreener.com
Cullinan Therapeutics (CGEM) Price Target Revised by UBS Analyst - GuruFocus
Cullinan Therapeutics Inc Reports Q1 2025 EPS Below Estimates wi - GuruFocus
Cullinan Therapeutics Reports Q1 2025 Financial Results - TipRanks
Cullinan Therapeutics: Q1 Earnings Snapshot - New Haven Register
Dimensional Fund Advisors LP Acquires 295,467 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - GlobeNewswire
Cullinan Oncology (CGEM) Projects Financial Runway through 2028 | CGEM Stock News - GuruFocus
Cullinan Therapeutics (CGEM) Advances Autoimmune and Oncology Programs | CGEM Stock News - GuruFocus
Finanzdaten der Cullinan Therapeutics Inc-Aktie (CGEM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.30%
3.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):